Among the array of nanoparticles being currently investigated as drug delivery systems, lipid-based nanocarriers have taken the lead due to their higher degree of biocompatibility and versatility, and they are commercially viable to formulate pharmaceuticals. They have shown to reduce the toxicity of various drugs by changing the biodistribution of the drugs, allowing for more drugs to be administered or reduce known side effects of the free drug. This forms the basis for the success of several marketed lipid-based nanomedicines for cancers (Doxil®, Myocet®; Onivyde®; Vyxeos®), for fungal infection (Ambisome®) and for macular degeneration (Visudyne®).
18/11/2021
Prof Khuloud Al-Jamal-King's College London 11.00, Aula Carelli, CU019